Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Current Assets (2017 - 2025)

Puma Biotechnology's Current Assets history spans 9 years, with the latest figure at $162.7 million for Q4 2025.

  • For Q4 2025, Current Assets rose 10.18% year-over-year to $162.7 million; the TTM value through Dec 2025 reached $162.7 million, up 10.18%, while the annual FY2025 figure was $162.7 million, 10.18% up from the prior year.
  • Current Assets reached $162.7 million in Q4 2025 per PBYI's latest filing, up from $143.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $167.8 million in Q2 2021 to a low of $111.8 million in Q1 2023.
  • Average Current Assets over 5 years is $138.5 million, with a median of $137.3 million recorded in 2021.
  • Peak YoY movement for Current Assets: tumbled 31.88% in 2022, then rose 27.98% in 2024.
  • A 5-year view of Current Assets shows it stood at $140.0 million in 2021, then decreased by 4.1% to $134.3 million in 2022, then increased by 16.31% to $156.2 million in 2023, then fell by 5.46% to $147.7 million in 2024, then increased by 10.18% to $162.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Current Assets are $162.7 million (Q4 2025), $143.6 million (Q3 2025), and $136.6 million (Q2 2025).